Preeclampsia Drug Pipeline — PatSnap Eureka
sFlt-1 siRNA, Angiogenic Restoration & Emerging Preeclampsia Therapeutics
Preeclampsia affects 5–8% of pregnancies worldwide with no approved disease-modifying therapy beyond delivery. Explore the emerging pipeline of sFlt-1-targeting RNAi, PlGF supplementation, immunomodulatory agents, and repurposed drugs — mapped from patent and literature intelligence.
The sFlt-1/VEGF/PlGF Angiogenic Axis: Central to Preeclampsia Pathology
Retrieved results converge on a well-defined molecular axis: excess circulating soluble fms-like tyrosine kinase-1 (sFlt-1, also designated VEGFR-1) acting as a decoy receptor that sequesters vascular endothelial growth factor (VEGF) and placental growth factor (PlGF), reducing their systemic bioavailability and precipitating maternal endothelial dysfunction. As stated explicitly in one review from the University of Mississippi Medical Center, "a hallmark characteristic of preeclampsia, especially early-onset preeclampsia, is angiogenic imbalance resulting from an inappropriately upregulated sFlt-1 acting as a decoy receptor binding VEGF and PlGF."
Among 348 women with preeclampsia, those with hemolysis, elevated liver enzymes, or low platelet count (HELLP) syndrome had sFlt-1 levels 2.63-fold higher and sFlt-1/PlGF ratios 10.07-fold higher than those without severe features. Soluble endoglin (sEng), produced through MMP-14-mediated cleavage of full-length endoglin on the syncytiotrophoblast surface, is identified as a secondary anti-angiogenic driver.
Additional targets flagged in retrieved results include the FLT1 alternative polyadenylation isoform sFlt-1-e15a (the most pathologically abundant placental isoform in early-onset disease), Endothelin-1 (ET-1) receptor type A, Marinobufagenin (MBG), PPARγ, and the NF-κB pathway regulating over 400 genes involved in inflammation, angiogenesis, and oxidative stress. Research from WHO and NIH continues to highlight preeclampsia as a priority maternal health target globally. PatSnap's life sciences intelligence platform enables researchers to map this rapidly evolving target landscape.
Quantifying the Angiogenic Imbalance & Pipeline Breadth
Key data points from patent and literature analysis illustrating disease severity markers and the distribution of therapeutic modalities in the preeclampsia pipeline.
sFlt-1 & sFlt-1/PlGF Ratio Elevation by Severity (n=348)
Among 348 women with preeclampsia, HELLP syndrome patients showed 2.63× higher sFlt-1 and 10.07× higher sFlt-1/PlGF ratio versus non-severe cases.
Preeclampsia Pipeline: 7 Therapeutic Modalities Identified
Innovation activity is predominantly literature-driven (academic papers), with commercial IP concentrated in the BIDMC patent family across Israeli and Spanish jurisdictions.
Seven Emerging Approaches in the Preeclampsia Drug Pipeline
From placenta-targeted siRNA nanoparticles to immunomodulatory biologics, the pipeline spans multiple mechanistic strategies — all targeting the core angiogenic and inflammatory dysfunction of preeclampsia.
sFlt-1 siRNA via Trophoblast-Targeted Nanoparticles
A placenta-targeted siRNA system using PEG-PLA nanoparticles surface-modified with a chondroitin sulfate A-binding peptide (P-CSA-BP) demonstrated selective placental accumulation in vivo, with RT-PCR and ELISA confirming reductions in both sFlt-1 mRNA and protein. Published by investigators at Shandong Provincial Hospital (2020). A complementary adenoviral approach showed sFlt-1 levels above 50 ng/mL plasma induced severe glomerular damage, reversed by co-administration of neutralizing constructs.
Preclinical proof-of-concept · Shandong Provincial HospitalAngiogenic Factor Restoration: VEGF, PlGF Supplementation
Administration of either VEGF or PlGF attenuated hypertension and proteinuria in multiple animal models. Beth Israel Deaconess Medical Center holds a family of patents across multiple jurisdictions disclosing methods for treating preeclampsia using compounds that increase VEGF or PlGF levels, decrease sFlt-1 levels, or inhibit the binding of VEGF/PlGF to sFlt-1. Placenta-targeted nanoparticle delivery of PFKFB3-overexpression plasmids (Huazhong University, 2022) represents a complementary metabolic-glycolytic approach.
Patents (BIDMC) + Preclinical papers · Multiple jurisdictionsProton Pump Inhibitors, Metformin & Statins
Esomeprazole reduced sFlt-1 secretion from primary cytotrophoblasts and mitigated endothelial dysfunction markers (VCAM-1, ET-1) in human cell models (University of Melbourne, 2022). Combining metformin and esomeprazole was found to additively reduce sFlt-1 and sEng secretion from placental and endothelial cells in vitro. Pravastatin exhibits pro-angiogenic, anti-inflammatory, and antioxidant pleiotropic effects with preclinical activity in animal models, though model-dependent variability was reported.
Preclinical · University of Melbourne / Mercy HospitalPD-1/PD-L1 Pathway & CD4+ T Cell Rebalancing
Immune dysregulation — specifically CD4+ T cell imbalance (Treg/Th17) — is a tractable therapeutic target. The PD-1/PD-L1 pathway was shown to be downregulated in preeclampsia, and administration of PD-L1-Fc fusion protein reversed the Treg/Th17 imbalance and produced protective maternal and fetal effects in L-NAME rat models (Yale University School of Medicine, 2016). A separate review from the University of Iowa (2022) maps broader immunomodulatory therapies as promising for preeclampsia prevention.
Preclinical · Yale University / University of IowaPeptide Biologics, Antioxidants & Cell-Based Strategies
Beyond RNAi and small molecules, emerging approaches target oxidative stress, heme scavenging, and mesenchymal stromal cell biology in preclinical preeclampsia models.
Alpha-1-Microglobulin (A1M)
A human endogenous heme-scavenging protein that significantly reduced hypertension in the STOX1 preeclampsia mouse model and ameliorated preeclampsia-like symptoms in a rabbit model of fetal hemoglobin-induced oxidative stress (Lund University). Orphan drug status was noted as a pathway to facilitate its development.
Resveratrol: Preclinical + Clinical Signal
Resveratrol reduced sFlt-1, sFlt-1-e15a, and sEng secretion from trophoblasts and HUVECs, and reduced NF-κB, IL-6, IL-1β, and TNFα in vitro. A randomized clinical study of 400 patients found that resveratrol + nifedipine combination reduced time to blood pressure control versus nifedipine alone — the closest clinical evidence signal in this dataset.
Preeclampsia Drug Candidates: Assignees, Evidence & Stage
A structured view of key therapeutic candidates retrieved from patent and literature datasets, organized by modality, lead institution, and evidence stage.
| Therapeutic Candidate / Approach | Lead Assignee / Institution | Mechanism | Evidence Stage |
|---|---|---|---|
| PEG-PLA + P-CSA-BP siRNA NPs (sFlt-1 silencing) | Shandong Provincial Hospital (2020) | Trophoblast-targeted RNAi → sFlt-1 mRNA/protein reduction | Preclinical |
| VEGF / PlGF supplementation | Beth Israel Deaconess Medical Center / Harvard | Angiogenic factor restoration; sFlt-1 binding inhibition | Patent (IL, ES) |
| PFKFB3 plasmid nanoparticles | Huazhong University of Science & Technology (2022) | Placental glycolysis enhancement → angiogenesis | Preclinical |
| Esomeprazole (PPI) | University of Melbourne / Mercy Hospital (2022) | sFlt-1 & sEng secretion reduction; renin-angiotensin modulation | Preclinical |
| Metformin + Esomeprazole (combination) | University of Melbourne (2018) | Additive sFlt-1 & sEng reduction; endothelial dysfunction reduction | Preclinical |
| PD-L1-Fc fusion protein | Yale University School of Medicine (2016) | Treg/Th17 rebalancing via PD-1/PD-L1 pathway restoration | Preclinical |
| Resveratrol + Nifedipine | Multiple institutions | NF-κB, IL-6, TNFα suppression; sFlt-1/sEng reduction | RCT (n=400) |
| Alpha-1-Microglobulin (A1M) | Lund University; University Hospital Basel | Heme scavenging; oxidative stress reduction | Orphan Drug Signal |
Need a Complete Pipeline Map with Filing Dates & Legal Status?
PatSnap Eureka surfaces patent family status, assignee transfers, and citation networks for every candidate above.
What Clinical Evidence Exists — and What Remains Preclinical
Retrieved results yield limited but notable clinical signals. The resveratrol + nifedipine RCT (400 patients) is the closest signal to clinical evidence in this dataset: the addition of resveratrol to oral nifedipine significantly reduced time to blood pressure control and time to new hypertensive crisis. ClinicalTrials.gov and the WHO ICTRP registry searches from a 2022 systematic evaluation (Burnet Institute / AIM Project) identified multiple categories of biologicals, drugs, and dietary supplements in active investigation for preeclampsia.
Anti-MBG antibody (Digibind) immunoneutralization of marinobufagenin was reported to reduce blood pressure in preeclamptic patients in a clinical context, with umbilical artery fibrosis documented in 11 patients with PE versus 10 gestational age-matched controls. At least two biotech companies working on antithrombin and A1M obtained orphan disease status from US/EU agencies, unlocking market exclusivity and R&D assistance.
No retrieved results describe Phase 2 or Phase 3 clinical trial outcomes for sFlt-1 siRNA, complement inhibitors, or PlGF supplementation specifically. The field remains predominantly preclinical, with commercial IP concentrated in the BIDMC patent family. PatSnap customers in pharma and biotech use Eureka to identify these gaps before committing to IND-enabling programs. PatSnap's life sciences solutions are purpose-built for this type of pipeline intelligence work.
Synergistic Strategies & Emerging Nanotechnology Platforms
Retrieved results signal several combination approaches and platform technologies that could accelerate the preeclampsia pipeline toward clinical translation.
Metformin + Esomeprazole: Additive sFlt-1 & sEng Suppression
The most explicitly characterized combination strategy in this dataset, with demonstrated additive suppression of both sFlt-1 and sEng from placental and endothelial cells in vitro (University of Melbourne, 2018). Both agents are clinically established, creating an accessible repurposing pathway with favorable safety profiles in pregnancy contexts.
Additive effect confirmed in vitro · Repurposing pathwayPlacenta-Homing Nanotechnology: Multi-Payload Delivery Platform
PEG-PLA + P-CSA-BP nanoparticles (Shandong) and CGKRK peptide-modified liposomes for PFKFB3 (Huazhong) represent an emerging placenta-homing nanotechnology platform that could accommodate multiple payloads — siRNA, expression plasmids, or small molecules — with reduced systemic exposure. PatSnap analytics can map the IP landscape for placenta-targeted delivery vectors.
siRNA + plasmid + small molecule payload flexibilityPreeclampsia Drug Pipeline — Key Questions Answered
The dominant therapeutic target across this dataset is sFlt-1 (soluble fms-like tyrosine kinase-1, also designated VEGFR-1). sFlt-1 acts as a decoy receptor that sequesters VEGF and PlGF, reducing their systemic bioavailability and precipitating maternal endothelial dysfunction. Both patent families and independent academic literature converge on sFlt-1 reduction or VEGF/PlGF pathway restoration as the central intervention strategy.
Retrieved results yield limited but notable clinical signals. A randomized study of 400 preeclamptic patients demonstrated that the addition of resveratrol to oral nifedipine significantly reduced time to blood pressure control and time to new hypertensive crisis. Anti-MBG antibody (Digibind) was reported to reduce blood pressure in preeclamptic patients in a clinical context, and umbilical artery fibrosis was documented in 11 patients with PE versus 10 gestational age-matched controls. No retrieved results describe Phase 2 or Phase 3 clinical trial outcomes for sFlt-1 siRNA, complement inhibitors, or PlGF supplementation specifically.
The most direct RNA interference approach in this dataset is a placenta-targeted siRNA system using PEG-PLA nanoparticles surface-modified with a chondroitin sulfate A-binding peptide (P-CSA-BP) to achieve trophoblast-specific sFlt-1 gene silencing. Published by investigators at Shandong Provincial Hospital, the system demonstrated selective placental accumulation in vivo, with RT-PCR and ELISA confirming reductions in both sFlt-1 mRNA and protein. This represents a preclinical proof-of-concept for RNAi-mediated sFlt-1 suppression.
Retrieved results document preclinical evidence for three repurposed drug classes: esomeprazole (proton pump inhibitor), which reduced sFlt-1 secretion from primary cytotrophoblasts and mitigated endothelial dysfunction markers; metformin combined with esomeprazole, which additively reduced sFlt-1 and sEng secretion from placental cells and endothelial cells; and pravastatin, which exhibits pro-angiogenic, anti-inflammatory, and antioxidant pleiotropic effects with preclinical activity demonstrated in animal models, though model-dependent variability was reported.
Soluble endoglin (sEng) is identified as a secondary anti-angiogenic driver in preeclampsia. It is produced through MMP-14-mediated cleavage of full-length endoglin on the syncytiotrophoblast surface and is co-elevated with sFlt-1 in severe and early-onset disease. MMP-14 inhibition was partially effective in reducing sEng production, though additional protease pathways (including MMP-15) appear contributory. Multiple therapeutic agents including resveratrol, esomeprazole, metformin, and hydroxychloroquine show preclinical activity in reducing both sFlt-1 and sEng simultaneously.
The most prominent patent assignee in this dataset is Beth Israel Deaconess Medical Center (BIDMC), which holds at least four patent records directed to methods of diagnosing, treating, or preventing preeclampsia using compounds that modulate VEGF, PlGF, or sFlt-1 levels, filed across Israeli and Spanish jurisdictions. The most prolific academic group is the University of Melbourne / Mercy Hospital for Women, contributing multiple papers across sFlt-1 biology, esomeprazole, metformin combinations, hydroxychloroquine, and resveratrol. Innovation activity is predominantly literature-driven, with commercial IP concentrated in the BIDMC patent family.
Still have questions? Let PatSnap Eureka search the patent and literature evidence for you.
Ask Eureka About Preeclampsia TherapeuticsAccelerate Your Preeclampsia Research with AI Patent Intelligence
Join 18,000+ innovators already using PatSnap Eureka to map drug pipelines, identify white space, and track emerging assignees across maternal health and reproductive medicine.
References
- Angiogenic Imbalance in Preeclampsia — University of Mississippi Medical Center (PatSnap Eureka Literature)
- sFlt-1 and sFlt-1/PlGF Ratio in 348 Women with Preeclampsia — University of Melbourne / Mercy Hospital (PatSnap Eureka Literature)
- MMP-14-Mediated Soluble Endoglin (sEng) Production in Preeclampsia (PatSnap Eureka Literature)
- FLT1 Alternative Polyadenylation Isoforms and NRIP1 in Early-Onset Preeclampsia — BIDMC / Harvard (PatSnap Eureka Literature)
- Trophoblast-Targeted Nanomedicine Modulates Placental sFLT1 for Preeclampsia Treatment — Shandong Provincial Hospital (2020) (PatSnap Eureka Literature)
- Reduction of Circulating Soluble Flt-1 Alleviates Preeclampsia-Like Symptoms in a Mouse Model — Helmholtz Centre (2010) (PatSnap Eureka Literature)
- Compounds for Treating and Preventing Pre-Eclampsia — Beth Israel Deaconess Medical Center (2020, IL) (PatSnap Eureka Patent)
- Placental Growth Factor and Pre-Eclampsia — Liverpool Hospital / University of New South Wales (2017) (PatSnap Eureka Literature)
- Placenta-Targeted Nanoparticles Loaded with PFKFB3 Overexpression Plasmids Enhance Angiogenesis — Huazhong University (2022) (PatSnap Eureka Literature)
- Assessment of Esomeprazole on Pathophysiological Markers of Preeclampsia — University of Melbourne (2022) (PatSnap Eureka Literature)
- Combining Metformin and Esomeprazole is Additive in Reducing sFlt-1 — University of Melbourne (2018) (PatSnap Eureka Literature)
- The PD-1/PD-L1 Inhibitory Pathway is Altered in Pre-Eclampsia — Yale University School of Medicine (2016) (PatSnap Eureka Literature)
- Resveratrol Reduces sFlt-1, sEng, and Inflammatory Cytokines in Trophoblasts (PatSnap Eureka Literature)
- Resveratrol + Nifedipine RCT in 400 Preeclamptic Patients (PatSnap Eureka Literature)
- MZe786 Hydrogen Sulfide-Releasing Molecule Inhibits sFlt-1 in RUPP Mouse Model (PatSnap Eureka Literature)
- Alpha-1-Microglobulin Reduces Hypertension in STOX1 Preeclampsia Mouse Model — Lund University (PatSnap Eureka Literature)
- Orphan Drug Designation for Preeclampsia: A1M and Antithrombin (PatSnap Eureka Literature)
- Human Placenta-Derived MSC Conditioned Media in LPS-Induced Mouse PE Model (PatSnap Eureka Literature)
- Systematic Pipeline Review of Preeclampsia Candidates 2000–2021 — Burnet Institute / AIM Project (2022) (PatSnap Eureka Literature)
- World Health Organization (WHO) — Maternal Health Research
- National Institutes of Health (NIH) — Preeclampsia Research Programs
- ClinicalTrials.gov — Preeclampsia Clinical Trial Registry
All data and statistics on this page are sourced from the references above and from PatSnap's proprietary innovation intelligence platform. This report represents a snapshot of innovation signals within a targeted patent and literature dataset only and should not be interpreted as a comprehensive view of the full field, clinical pipeline, or regulatory landscape.
PatSnap Eureka searches patents and research to answer instantly.